Griffiths Ulla K, Wolfson Lara J, Quddus Arshad, Younus Mohammed, Hafiz Rehan A
Department of Immunization, Vaccines, and Biologicals, World Health Organization, 1211 Geneva 27, Switzerland.
Bull World Health Organ. 2004 Sep;82(9):643-51.
This study aimed to estimate the incremental cost-effectiveness of supplementary immunization activities to prevent neonatal tetanus in the Loralai district of Pakistan. The supplemental immunization activities were carried out in two phases during 2001-03.
A state-transition model was used to estimate the effect of routine vaccination with tetanus toxoid as well as vaccination with tetanus toxoid during supplementary immunization activities. The model follows each woman in the target population from birth until the end of her childbearing years, using age-specific fertility data and vaccination history to determine the number of births at risk for neonatal tetanus. Recently published data on the incidence of neonatal tetanus from Loralai were used to determine the number of cases occurring with and without supplementary immunization activities. Data on the costs of the activities were collected from the UNICEF office in Balochistan and from the Provincial Health Department.
Using base-case assumptions we estimated that the supplementary immunization activities would prevent 280 cases of neonatal tetanus and 224 deaths from neonatal tetanus between 2001 and 2034. Implementation of the supplementary activities was relatively inexpensive. The cost per tetanus toxoid dose delivered was 0.40 U.S. dollars. In the base-case analysis the cost per death averted was 117.00 U.S. dollars (95% confidence interval (CI) = 78-205 U.S. dollars) and the cost per disability-adjusted life year (DALY) averted was 3.61 U.S. dollars (95% Cl = 2.43-6.39 U.S. dollars).
Compared with similar analyses of other interventions, the cost per DALY averted is a favourable cost-effectiveness ratio. However, if routine diphtheria-tetanus-pertussis vaccination coverage in the Loralai district had been higher (at a coverage rate of about 80%) the cost-effectiveness of the intervention would have been even more favourable, at 2.65 U.S. dollars per DALY averted.
本研究旨在评估在巴基斯坦洛拉莱地区开展补充免疫活动预防新生儿破伤风的增量成本效益。补充免疫活动于2001年至2003年分两个阶段进行。
采用状态转换模型来评估破伤风类毒素常规接种以及补充免疫活动期间破伤风类毒素接种的效果。该模型跟踪目标人群中每位女性从出生到育龄期末的情况,利用特定年龄的生育率数据和接种史来确定有新生儿破伤风风险的出生人数。使用洛拉莱最近公布的新生儿破伤风发病率数据来确定在开展和未开展补充免疫活动情况下发生的病例数。活动成本数据从联合国儿童基金会俾路支省办事处和省卫生部门收集。
根据基本假设,我们估计补充免疫活动在2001年至2034年期间将预防280例新生儿破伤风病例和224例新生儿破伤风死亡。补充活动的实施成本相对较低。每剂破伤风类毒素的交付成本为0.40美元。在基本情况分析中, avert per death averted为117.00美元(95%置信区间(CI)=78 - 205美元), avert per disability-adjusted life year (DALY) averted为3.61美元(95% Cl = 2.43 - 6.39美元)。
与其他干预措施的类似分析相比, avert per DALY averted是一个有利的成本效益比。然而,如果洛拉莱地区白喉-破伤风-百日咳常规疫苗接种覆盖率更高(覆盖率约为80%),则该干预措施的成本效益将更有利, avert per DALY averted为2.65美元。